News PTC's Huntington study was positive. Why did its stock fall? In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.
News Novartis pays $1bn upfront for Huntington's drug from PTC Novartis has made a return to the Huntington's disease stage by licensing an oral mRNA splicer from PTC Therapeutics for $1 billion upfront.
News Boehringer targets NASH/MASH with $2bn Ribo alliance Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or
Partner Content Partner Content RNA Therapy Improves Vision in Child Blindness-More developm... 10th Annual RNA Therapeutics returns to London
Partner Content Partner Content MiNA Therapeutics Chief Scientific Officer to speak at RNA T... CSO of MiRNA Therapeutics to speak at RNA Therapeutics
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.